UroStream

In recent years, prostate-specific membrane antigen (PSMA) molecular imaging technology has demonstrated significant value in the diagnosis and treatment of prostate cancer. It has improved the accuracy of clinical staging, supported multimodal treatment decision-making, and facilitated the development of precision medicine through novel radioligand therapies. At the recent EAU Congress, UroStream invited Professor Xuefeng Qiu from Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School,Nanjing University, to share insights into his team’s research on PSMA PET/CT for predicting biochemical recurrence (BCR), the impact of tumor heterogeneity, and the clinical experience at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School，Nanjing University.

At the highly anticipated Game Changer Session at EAU25, Professor Declan Murphy (Peter MacCallum Cancer Centre, Melbourne) delivered an impactful presentation on the results of the TRANSLATE trial, a multicentre,…

In a Game Changer Session at EAU25, Prof. Kellokumpu-Lehtinen Pirkko-Liisa presented the 10-year follow-up from the Scandinavian Prostate Cancer Study Group-13 trial (SPCG-13), exploring adjuvant docetaxel versus surveillance following curative…

At EAU25, Dr. Mehmet Cetin from Marmara University School of Medicine (Istanbul) presented a prospective randomized controlled study evaluating the impact of video-based informed consent on the anxiety levels of…

At #EAU25, Professor Xiongjun Ye (叶雄俊) from Peking Union Medical College Hospital shared his team’s latest findings on MRI accuracy in renal tumor diagnosis, tumor heterogeneity in RCC, and strategies for managing postoperative recurrence. His group’s EAU-selected research explores how imaging limitations and intratumoral heterogeneity affect treatment outcomes—offering new perspectives for optimizing RCC care.

At #EAU25, we spoke with Prof. Haibin Chen and Prof. Ruiyi Zhang from Renji Hospital, Shanghai Jiao Tong University, who shared updates on their team's research in muscle-invasive bladder cancer (MIBC). They discussed a new study exploring ADC therapy for HER2+ MIBC, as well as progress in bladder-sparing treatment, ctDNA-based monitoring, and AI-driven molecular profiling for personalized treatment decisions.

At hashtag#EAU25, Prof. Shousheng Chen (陈守臻) from Qilu Hospital of Shandong University shared key findings from his study on a "biopsy-free" diagnostic approach for prostate cancer using PSMA PET/CT, mpMRI, and serum biomarkers. He discussed how this strategy compares with traditional PSA and DRE, its potential in early diagnosis, and how it could guide follow-up and monitoring.

At hashtag#EAU25 in Madrid, we had the opportunity to interview Professor Liangyou Gu from the General Hospital of the Chinese PLA, who shared his clinical perspective on emerging treatment strategies for muscle-invasive bladder cancer (MIBC). With ongoing breakthroughs in MIBC research, bladder-sparing approaches are gaining traction alongside radical cystectomy. Prof. Gu offered his insights on how clinicians can evaluate the best option for each patient, especially in the context of neoadjuvant therapy.

At the 40th Annual European Association of Urology (EAU) Congress, precision biopsy strategies and technological innovation were core topics in the prostate cancer field. With a focus on addressing the limitations of traditional systematic biopsies and MRI-targeted biopsies, multiple studies concentrated on optimizing biopsy approaches to balance diagnostic efficacy and safety. "UroStream" invited Professors Kan Gong and Yi Liu from Peking University First Hospital, along with Dr. Ruiyi Deng, to discuss the latest advancements in prostate cancer biopsy at the EAU conference, their team’s peri-lesion biopsy RCT study findings, and cutting-edge precision biopsy approaches.